Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
19
MEDIF Quote, Financials, Valuation and Earnings
Last price:
$0.04
Seasonality move
:
13.38%
Day range:
$0.04 - $0.05
52-week range:
$0.04 - $0.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.58x
P/B ratio:
0.71x
Volume:
55.9K
Avg. volume:
189.9K
1-year change:
-6.78%
Market cap:
$19.2M
Revenue:
$30.6M
EPS (TTM):
-$0.01
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, MediPharm Labs Corp. has -- downside to fair value with a price target of -- per share.
MEDIF vs. S&P 500
-
Over the past 5 trading days, MediPharm Labs Corp. has overperformed the S&P 500 by 7.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MediPharm Labs Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MediPharm Labs Corp. has grown year-over-year revenues for 11 quarters straight. In the most recent quarter MediPharm Labs Corp. reported revenues of $8.3M.
Earnings Growth
-
MediPharm Labs Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter MediPharm Labs Corp. reported earnings per share of -$0.00.
Enterprise value:
11.9M
EV / Invested capital:
0.43x
Price / LTM sales:
0.58x
EV / EBIT:
--
EV / Revenue:
0.36x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.3M
Return On Assets:
-15.67%
Net Income Margin (TTM):
-17.53%
Return On Equity:
-19.3%
Return On Invested Capital:
-19.11%
Operating Margin:
-18.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $21.9M | $28.7M | $33M | $7.2M | $8.3M | |
| Gross Profit | $2.2M | $8.7M | $9.3M | $2.7M | $1.8M | |
| Operating Income | -$16.2M | -$8.5M | -$6.4M | -$1.4M | -$1.6M | |
| EBITDA | -$14.4M | -$6.5M | -$5.1M | -$1.1M | -$1.2M | |
| Diluted EPS | -$0.04 | -$0.02 | -$0.01 | -$0.00 | -$0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $67M | $38M | $30.8M | $25.6M | $20.1M | |
| Total Assets | $93.3M | $51.8M | $50.3M | $41.3M | $33.5M | |
| Current Liabilities | $12.2M | $7.8M | $9.4M | $8M | $6.3M | |
| Total Liabilities | $12.3M | $7.8M | $9.5M | $8M | $6.3M | |
| Total Equity | $81M | $44M | $40.8M | $33.3M | $27.2M | |
| Total Debt | $1.8M | $95.4K | $669.3K | $484.1K | $304K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10M | -$1.4M | -$4.9M | -$470.7K | -$100.3K | |
| Cash From Investing | $6.1M | $3.5M | $3.3M | -$24.2K | $347.6K | |
| Cash From Financing | -$790.9K | -$1.7M | -$173.9K | -$1.6M | -$86.6K | |
| Free Cash Flow | -$10.5M | -$1.5M | -$5M | -$494.9K | -$112.2K | |
MEDIF
Sector
Market Cap
$19.2M
$28.8M
Price % of 52-Week High
53.74%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
1.42%
-1.32%
1-Year Price Total Return
-6.78%
-20.64%
Beta (5-Year)
0.510
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.04
200-day SMA
Sell
Level
$0.06
Bollinger Bands (100)
Sell
Level
0.05 - 0.05
Chaikin Money Flow
Buy
Level
1.7M
20-day SMA
Sell
Level
$0.05
Relative Strength Index (RSI14)
Sell
Level
44.25
ADX Line
Sell
Level
36.39
Williams %R
Neutral
Level
-66.2948
50-day SMA
Sell
Level
$0.05
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
200.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.9114)
Buy
CA Score
(Annual)
Level (0.3777)
Buy
Beneish M-Score
(Annual)
Level (-3.278)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (1.6234)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. It focuses on the downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. It supplies raw materials, formulations, processing, and packaging for the creation of ready-to-sell derivative products. The company was founded by Patrick McCutcheon and Keith Strachan in 2015 and is headquartered in Barrie, Canada.
Stock Forecast FAQ
In the current month, MEDIF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MEDIF average analyst price target in the past 3 months is --.
-
Where Will MediPharm Labs Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that MediPharm Labs Corp. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About MediPharm Labs Corp.?
Analysts are divided on their view about MediPharm Labs Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MediPharm Labs Corp. is a Sell and believe this share price will rise from its current level to --.
-
What Is MediPharm Labs Corp.'s Price Target?
The price target for MediPharm Labs Corp. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MEDIF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MediPharm Labs Corp. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MEDIF?
You can purchase shares of MediPharm Labs Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MediPharm Labs Corp. shares.
-
What Is The MediPharm Labs Corp. Share Price Today?
MediPharm Labs Corp. was last trading at $0.04 per share. This represents the most recent stock quote for MediPharm Labs Corp.. Yesterday, MediPharm Labs Corp. closed at $0.05 per share.
-
How To Buy MediPharm Labs Corp. Stock Online?
In order to purchase MediPharm Labs Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MEDIF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MEDIF
Sector
P/E ratio
--
23.71x
PEG ratio
--
-0.01x
P/B ratio
0.71x
1.84x
Price / LTM sales
0.58x
1.60x
Growth Metrics
MEDIF
Sector
Revenue growth
15.71%
4.85%
Earnings growth
24.49%
11.15%
Revenue (5-year growth)
-20.66%
6.45%
Earnings forecast
--
-$0.20
Profitability
MEDIF
Sector
Profitability FY 2024
$8.3M
$3.6M
Return on invested capital
-19.11%
-30.98%
Return on assets
-15.67%
-27.62%
Return on equity
-19.3%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
12
Balance Sheet
MEDIF
Sector
Total cash
$7.6M
$27.2M
Short term investments
--
$25.7M
Total assets
$37.4M
$79.7M
Long term debt
$304K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 195.13% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 0.37% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 2% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
